Paraoxonase 1 in Chronic Kidney Failure

Gugliucci, Alejandro; Kotani, Kazuhiko; Kimura, Satoshi

doi:10.1155/2012/726048

Cited by 52 publications

(51 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PON1 protects HDL-C and LDL-C from oxidation, 1,2 inhibits oxidation of lipids in macrophages and erythrocytes, and stimulates macrophage cholesterol efflux. 3,4 . Moreover, PON1 is involved in the antiatherogenic activity of HDL-C by preventing the formation of oxidized LDL.…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, PON1 is involved in the antiatherogenic activity of HDL-C by preventing the formation of oxidized LDL. 5,6 Most of the PON1 activity carried by HDL-C is found in the HDL3-C small subfraction of HDL-C. 4,7,8 Patients with chronic kidney disease (CKD) on hemodialysis (HD) are exposed to several risk factors for atherosclerosis, such as oxidative stress, endothelial dysfunction and dyslipidemia. [9][10][11] Dyslipidemia is mainly associated with low serum levels of HDL-C, high levels of triglycerides and elevated levels of triglyceriderich lipoproteins or lipoprotein-remnants.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease

et al. 2016

View full text Add to dashboard Cite

Patients with chronic kidney disease (CKD) are at high risk of atherosclerotic events; dyslipoproteinemia and the decrease of the HDL-linked enzyme paraoxonase 1 (PON1), might have a major role. This study intends to compare the association between lipid profile and serum PON1 levels in renal failure (RF) and hemodialysis (HD) patients. Serum lipids, HDL-subclasses and PON1 concentration were evaluated in 90 patients with CKD, divided into groups: RF (n ¼ 46) and HD (n ¼ 44), and in 30 normal individuals (control group). The results showed that PON1 was significantly lower in HD patients than in RF and controls (p50.001). In RF patients under statin therapy, PON1 did not differ from that of patients without statins. In HD patients without statins, PON1 was considerably low, whereas in HD with statins (30.42 ± 12.62 mg/mL) was lower than RF with statins (49.31 ± 14.94, p50.001). PON1 concentration was significantly and positively associated with HDL-C, HDL3-C and Apo A1 in all groups. Additionally, in HD patients PON1 was negatively associated with LDL-C. Multiple regression analysis revealed that LDL-C and statin treatment were independently related to PON1 concentration in HD patients (b ¼ À0.331, p ¼ 0.026 and b ¼ 0.344, p ¼ 0.020, respectively). In RF patients, HDL3-C and Apo A1 are strong determinants of PON1 levels. It is concluded that different parameters of lipid profile seem to affect serum PON1 concentration of RF and HD patients and probably contribute to the delay of atherosclerosis.ARTICLE HISTORY

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Apesar de alguns pacientes com DRC desenvolverem doença renal em estágio final (DREF), a maioria deles morrem de DCV antes mesmo de chegar ao estágio final da doença renal 7,14,15 . A dislipidemia, tabagismo, diabetes mellitus, obesidade, hipertensão, idade avançada e sexo masculino são fatores de risco clássicos para o desenvolvimento de DCV.…”

Section: A Elevação Do Risco Cardiovascular Na Doença Renal Crônicaunclassified

“…Um dos principais distúrbios no processo de remodelagem do endotélio vascular é a calcificação que está intimamente ligada a alterações no metabolismo do cálcio como consequência da DRC 4,5 . Também é observada a presença de distúr-bios no metabolismo das lipoproteínas 6 , pois, apesar da concentração sérica do colesterol se apresentar entre os valores de referência, o paciente renal crônico apresenta a tríade aterogênica: hipertrigliceridemia, aumento sérico do colesterol da lipoproteína de muito baixa densidade (VLDL-C) e redução do colesterol das lipoproteínas de alta densidade (HDL-C), além de alterações qualitativas destas partículas, assim como alterações no metabolismo das apolipoproteínas A e B 7,8 . O aumento sérico dos triglicérides é a anormalidade quantitativa mais comum na DRC 9 .…”

Section: Introductionunclassified

Dislipidemia associada à doença renal crônica – Revisão de literatura

Marques¹,

Silva²,

Couto³

2015

cmbio

View full text Add to dashboard Cite

Introdução: A doença renal crônica (DRC) está associada com o desenvolvimento precoce da doença cardiovascular e morte prematura, decorrente de distúrbios do metabolismo das lipoproteínas e outras alterações que contribuem para a disfunção endotelial e consequente desenvolvimento de quadros dislipidêmicos com aterosclerose acelerada. Objetivo: Neste trabalho serão discutidos aspectos das alterações no metabolismo lipídico secundário à DRC. Metodologia: Foram selecionados artigos originais e de revisão publicados entre 1993 e 2014, em duas bases de dados bibliográficos – Literatura Internacional em Ciências da Saúde (PubMed) e Portal de Periódicos CAPES. Foram selecionados quarenta e sete artigos para a redação deste trabalho. Conclusão: Embora a dislipidemia seja um distúrbio observado na DRC, ainda existem diversos pontos-chave da regulação do metabolismo lipídico que necessitam ser esclarecidos. Assim, novos estudos deverão ser realizados para melhor compreensão do desenvolvimento da dislipidemia em paralelo ao avanço da doença renal crônica.

show abstract

“…It was reported that PON1 lactonase activity, stimulated by reconstituted HDL containing apo A-I, mediated the protection of LDL from oxidation and stimulated the HDL-mediated cholesterol efflux from macrophages [22]. Previous studies have demonstrated decreased PON1 lactonase activity in HD patients compared with healthy subjects [23][24][25], moreover; HD patients were found to be susceptible to lipid peroxidation, protein homocysteinylation and, hence, atherosclerosis [23,24]. PON1 lactonase activity was significantly lowered in patients with coronary artery disease (CAD) than in controls [26,27].…”

mentioning

confidence: 99%

Circulating Fibroblast Growth Factor-23 Level and Paraoxonase-1 Lactonase Activity in Chronic Hemodialysis Patients: Their Impact on the Incidence of Native AV Fistula Thrombosis

Zohny¹,

El-Fattah²,

Khan³

2016

CIM

View full text Add to dashboard Cite

Purpose: Thrombosis of native arteriovenous (AV) fistula is an important cause of complications in hemodialysis (HD) patients. The purpose of this study was to investigate the usefulness of measuring circulating fibroblast growth factor-23 (FGF-23) level and paraoxonase-1 (PON1) lactonase activity as potential predictors of native AV fistula thrombosis in chronic HD patients.Methods: This study included 83 HD patients (48 with thrombosed and 35 with non-thrombosed native AV fistulas) and 38 healthy volunteers. Serum FGF-23 level was measured using the ELISA technique, while serum PON1 lactonase activity was measured spectrophotometrically using gamma-thiobutyrolactone as a substrate.Results: FGF-23 was significantly increased while PON1 lactonase was markedly decreased in both thrombosed and non-thrombosed HD patients compared with controls (P < 0.001). FGF-23 was elevated whereas PON1 lactonase was decreased in HD patients with thrombosed native AV fistulas compared with HD patients with non-thrombosed native AV fistulas (P = 0.001 and 0.002, respectively). A significant negative correlation was found between FGF-23 and PON1 lactonase in HD patients with thrombosed native AV fistulas (r = −0.342, P = 0.017).Conclusions: This study shows a potential value of FGF-23 and PON1 lactonase as predictors of native AV fistula thrombosis in HD patients.

show abstract

Paraoxonase 1 in Chronic Kidney Failure

Cited by 52 publications

References 98 publications

Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease

Association of lipid profile with serum PON1 concentration in patients with chronic kidney disease

Dislipidemia associada à doença renal crônica – Revisão de literatura

Circulating Fibroblast Growth Factor-23 Level and Paraoxonase-1 Lactonase Activity in Chronic Hemodialysis Patients: Their Impact on the Incidence of Native AV Fistula Thrombosis

Contact Info

Product

Resources

About